Search Results - "Huang, Dennis Chin Lun"

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer by Schmid, Peter, Sablin, Marie-Paule, Bergh, Jonas, Im, Seock-Ah, Lu, Yen-Shen, Martínez, Noelia, Neven, Patrick, Lee, Keun Seok, Morales, Serafín, Pérez-Fidalgo, J Alejandro, Adamson, Douglas, Gonçalves, Anthony, Prat, Aleix, Jerusalem, Guy, Schlieker, Laura, Espadero, Rosa-Maria, Bogenrieder, Thomas, Huang, Dennis Chin-Lun, Crown, John, Cortés, Javier

“…Xentuzumab-a humanised IgG1 monoclonal antibody-binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling and suppressing AKT activation by…”
Get full text

A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma by Yen, Chia-Jui, Kim, Tae-You, Feng, Yin-Hsun, Chao, Yee, Lin, Deng-Yn, Ryoo, Baek-Yeol, Huang, Dennis Chin-Lun, Schnell, David, Hocke, Julia, Loembé, Arsène-Bienvenu, Cheng, Ann-Lii

“…Background: Nintedanib is an oral, triple angiokinase inhibitor of vascular endothelial growth factor/platelet-derived growth factor/fibroblast growth factor…”
Get full text

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors by Park, Keunchil, Tan, Daniel Shao Weng, Su, Wu-Chou, Cho, Byoung Chul, Kim, Sang-We, Lee, Ki Hyeong, Wang, Chin-Chou, Seto, Takashi, Huang, Dennis Chin-Lun, Jung, Helen Hayoun, Hsu, Ming-Chi, Bogenrieder, Thomas, Lin, Chia-Chi

“…Insulin-like growth factor signaling has been implicated in acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. This phase 1 trial…”
Get full text

Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial by Fan, Yun, Chen, Jianhua, Zhou, Chengzhi, Wang, Huijuan, Shu, Yongqian, Zhang, Jacky, Hua, Hairui, Huang, Dennis Chin-Lun, Zhou, Caicun

“…•Phase II analysis of the efficacy and safety of afatinib therapy for HER2m + NSCLC.•No patient achieved an overall response, and no clinical benefit was…”
Get full text

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours by de Bono, Johann, Lin, Chia-Chi, Chen, Li-Tzong, Corral, Jesus, Michalarea, Vasiliki, Rihawi, Karim, Ong, Michael, Lee, Jih-Hsiang, Hsu, Chih-Hung, Yang, James Chih-Hsin, Shiah, Her-Shyong, Yen, Chia-Jui, Anthoney, Alan, Jove, Maria, Buschke, Susanne, Fuertig, René, Schmid, Ulrike, Goeldner, Rainer-Georg, Strelkowa, Natalja, Huang, Dennis Chin-Lun, Bogenrieder, Thomas, Twelves, Chris, Cheng, Ann-Lii

“…Background Xentuzumab, an insulin-like growth factor (IGF)-1/IGF-2-neutralising antibody, binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling…”
Get full text

Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer by Zhao, Jun, Bai, Hua, Wang, Xin, Wang, Yuyan, Duan, Jianchun, Chen, Hanxiao, Xue, Zhiyi, Tian, Yahui, Cseh, Agnieszka, Huang, Dennis Chin-Lun, Wu, Yi-Long, Wang, Jie

Get full text

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies by Passaro, Antonio, de Marinis, Filippo, Tu, Hai-Yan, Laktionov, Konstantin K., Feng, Jifeng, Poltoratskiy, Artem, Zhao, Jun, Tan, Eng Huat, Gottfried, Maya, Lee, Victor, Kowalski, Dariusz, Yang, Cheng Ta, Srinivasa, BJ, Clementi, Laura, Jalikop, Tejaswini, Huang, Dennis Chin Lun, Cseh, Agnieszka, Park, Keunchil, Wu, Yi-Long

“…Background Afatinib is approved for first-line treatment of patients with epidermal growth factor receptor mutation-positive ( EGFR m+) non-small-cell lung…”
Get full text

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China by Tu, Hai-Yan, Feng, Jifeng, Shi, Meiqi, Zhao, Jun, Wang, Yuyan, Chang, Jianhua, Wang, Jialei, Cheng, Ying, Zhu, Jing, Tan, Eng-Huat, Li, Kai, Zhang, Yiping, Lee, Victor, Yang, Cheng-Ta, Su, Wu-Chou, Lam, David Chi-Leung, Srinivasa, B. J., Rajappa, Senthil, Ho, Ching-Liang, Lam, Kwok Chi, Hu, Yi, Bondarde, Shailesh Arjun, Liu, Xiaoqing, Tian, Yahui, Xue, Zhiyi, Cseh, Agnieszka, Huang, Dennis Chin-Lun, Zhou, Caicun, Wu, Yi-Long

“…Background Afatinib has been shown as a suitable option for the treatment of epidermal growth factor receptor mutation-positive ( EGFR m+) non-small-cell lung…”
Get full text

Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFR m+ non-small-cell lung cancer by Zhao, Jun, Bai, Hua, Wang, Xin, Wang, Yuyan, Duan, Jianchun, Chen, Hanxiao, Xue, Zhiyi, Tian, Yahui, Cseh, Agnieszka, Huang, Dennis Chin-Lun, Wu, Yi-Long, Wang, Jie

“…To explore the relationship between mutations in cfDNA and response to afatinib. In total, 64 patients from one Chinese site with locally advanced/metastatic…”
Get full text

Abstract CT165: An open label, multi-cohort, phase Ib study of xentuzumab and abemaciclib: Preliminary results from the advanced non-small cell lung cancer (NSCLC) cohort by LoRusso, Patricia, García-Corbacho, Javier, Braiteh, Fadi S., Gonçalves, Anthony, Ricci, Francesco, Iwata, Hiroji, Capelán, Marta, Sablin, Marie Paule, Prat, Aleix, Hardebeck, Molly Catherine, Puig, Marta, Huang, Dennis Chin-Lun, Hsu, Mingchi, Yee, Douglas

“…Abstract Introduction: Insulin-like growth factor (IGF) signaling and the cyclin D-cyclin-dependent kinase (CDK) 4 & 6-retinoblastoma pathway are implicated in…”
Get full text

Abstract P3-11-05: A phase Ib multi-cohort study of xentuzumab and abemaciclib in patients (pts) with solid tumors and breast cancer (BC) - Initial report of four dose-finding cohorts by Yee, Douglas, Oliveira, Mafalda, Iwata, Hiroji, Gonçalves, Anthony, García-Corbacho, Javier, Sablin, Marie Paule, Prat, Aleix, Hardebeck, Molly Catherine, Puig, Marta, Huang, Dennis Chin-Lun, Hsu, Mingchi, LoRusso, Patricia

“…Abstract Background: Insulin-like growth factor receptor-1 (IGF-1R) signaling is implicated in cancer progression, prognosis, and treatment resistance…”
Get full text